TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01462487

Intervention type: DRUG
Intervention: Treatment with zanamivir
Description: Subjects treated with zanamivir

Intervention type: DRUG
Intervention: Treatment with zanamivir
Description: Subjects treated with zanamivir

Intervention type: DRUG
Intervention: Treatment with zanamivir
Description: Subjects treated with zanamivir
Study: NCT02906332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg IV every 3 weeks x 2 cycles. This is followed by followed by pembrolizumab 200 mg IV every 3 weeks for 2 additional cycles.
Study: NCT04234464

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg
Description: Budesonide/albuterol sulfate combination inhalation aerosol single dose

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg
Description: Budesonide/albuterol sulfate combination inhalation aerosol single dose

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Placebo metered-dose inhaler
Description: Placebo inhalation aerosol single dose
Study: NCT02906332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 25 mg po daily x 14 days once weekly for a 21-day cycle x 2 cycles. This is followed by lenalidomide 25 mg po daily x 14 days for a 21-day cycle x 2 cycles for 2 additional cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 40 mg po once weekly for a 21-day cycle x 2 cycles only.
Study: NCT00526942

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SAAGE-designed, visual memory-based cognitive training
Description: Training sessions take 40 minutes per day, five days per week for a total goal of 15, 40-minute sessions.
Study: NCT02587793

Intervention type: OTHER
Intervention: not interventional study
Study: NCT03600701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT01393223

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LP-08 80mg
Description: Intravesical instillation of 80mg LP08

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Intravesical instillation of normal saline
Study: NCT04234464

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Placebo metered-dose inhaler
Description: Placebo inhalation aerosol single dose
Study: NCT05053724

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Star to move Protocol
Description: Progressive physical therapy according to the Gosslink protocol called Start to move.
Study: NCT03131479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIK066
Description: LIK066 50 mg tablets taken orally once daily before breakfast for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIK066
Description: LIK066 50 mg tablets taken orally once daily before breakfast for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIK066
Description: LIK066 50 mg tablets taken orally once daily before breakfast for 7 days.
Study: NCT00968253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisone
Description: 50 mg IV over 2 hours approximately every 12 hours for 6 doses days 1-3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisone
Description: 50 mg IV over 2 hours approximately every 12 hours for 6 doses days 1-3.
Study: NCT01393223

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LP-08 20mg
Description: Intravesical instillation of 20mg LP08
Study: NCT01422577

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bright Narrow Band Imaging
Description: It is a High Definition system with narrow band imaging option in th endoscope.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: White light Endoscopy
Description: White light Endoscopy
Study: NCT04221178

Intervention type: OTHER
Intervention: Cessation of continuous matinenace therapy
Description: Cessation of maintenance therapy for participants in sustained MRD-negative remission while under careful observation
Study: NCT03851757

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: waist-shaped interdental brush
Description: use four times each per interdental space

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cylindric interdental brush
Description: use four times each per interdental space
Study: NCT02351999

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TSP Crosser Transseptal Access System
Description: for transseptal puncture, left atrial access and catheter navigation.
Study: NCT02447939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib will be provided as 50 mg and 75 mg capsules. Each capsule will contain 50 mg or 75 mg of free base (present as the mesylate salt).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib study will be provided as 0.5 mg and 2.0 mg tablets. Each tablet will contain 0.5 mg or 2.0 mg of trametinib parent (present as the DMSO solvate)
Study: NCT06631924

Intervention type: DEVICE
Intervention: Implant
Description: Intramedullary headless hardware systems were utilized to place hardware in85 a retrograde manner from the metacarpophalangeal joint.
Study: NCT02513433

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Local anesthetic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Local anesthetic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: Local anesthetic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: Local anesthetic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Local anesthetic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Local anesthetic
Study: NCT01139697

Intervention type: OTHER
Intervention: Hair sampling
Description: Hair sampling for the measurement of cortisol and testosterone
Study: NCT04157166

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: to record a whole body 3D of 25 minutes in camera VERITON-CT ™
Description: The procedure of recording of 25 minutes in camera VERITON-CT ™ including the registration whole body 3D coupled to a scanner low dose (CT) will be added to conventional recording followed by complementary images SPECT/CT

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: to record a whole body 3D of 25 minutes in camera VERITON-CT ™
Description: The procedure of recording of 25 minutes in camera VERITON-CT ™ including the registration whole body 3D coupled to a scanner low dose (CT) will be added to conventional recording followed by complementary images SPECT/CT
Study: NCT01930279

Intervention type: OTHER
Intervention: Blood withdrawal
Description: Blood withdrawal
Study: NCT03390556

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse-delivered education
Description: The nurse will:~1. Give the caregiver and child an overview of asthma, and discuss asthma control, triggers, and medications.~2. Give caregivers information about asthma management written at or below 6th grade reading levels.~3. Provide colored medication labels to distinguish controller from rescue medications following the action plan color scheme (green for controller medications, red for rescue medications). Teach-back methods will be used to elicit understanding of correct indications of use.~4. Demonstrate MDI/spacer technique with teach-back.~5. Discuss age-appropriate caregiver and child responsibility for asthma management within the family, with an overview of transitioning responsibility.~6. Ask patients to make a 1 month follow-up appointment for asthma care.
Study: NCT01912495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir
Study: NCT02289560

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial ExAblate
Description: Transcranial ExAblate
Study: NCT02350595

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lean fish

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fatty fish
Study: NCT02889822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprostadil Liposomes for Injection
Description: 1. Single-dose tolerance test:10ug/20ug/50ug/100ug/200ug/300ug/400ug of Alprostadil Liposome for Injection,ivgtt,qd~2. Multiple-dose tolerance test:100ug,ivgtt,qd,continuous administration for 7 days.
Study: NCT02540213

Intervention type: DEVICE
Intervention: MIRCERA
Description: Methoxy polyethylene glycol epoetin beta (0.6 mcg/kg q2w) will be administered using MIRCERA ready-to-use-syringes up to 9 months.
Study: NCT01506843

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Mite, Mite and Bacterial or Placebo
Description: All treatments were given by sublingual route according to schedule of EAACI, with some modification. Patients received up-dosing sublingual drops once a day, reaching in approximately 3 months a monthly maintenance dose of 36 μg of Der p 1 given three times a week in alternate days for mite, mite and bacterial allergen extract, and no Der p 1 and no bacterial components in the placebo group. Doses were delivered by using vials equipped with a metered-dose dropper, and subjects were instructed to hold the solution under the tongue for 2 min and not to eat or drink for 60 min after the dose. Subjects self-administered the treatment at home. Adjustments in the schedule were made on an individual basis according to standard guidelines for specific immunotherapy

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mite, Mite and Bacterial or Placebo
Description: All treatments were given by sublingual route according to schedule of EAACI, with some modification. Patients received up-dosing sublingual drops once a day, reaching in approximately 3 months a monthly maintenance dose of 36 μg of Der p 1 given three times a week in alternate days for mite, mite and bacterial allergen extract, and no Der p 1 and no bacterial components in the placebo group. Doses were delivered by using vials equipped with a metered-dose dropper, and subjects were instructed to hold the solution under the tongue for 2 min and not to eat or drink for 60 min after the dose. Subjects self-administered the treatment at home. Adjustments in the schedule were made on an individual basis according to standard guidelines for specific immunotherapy
Study: NCT00968253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 10 mcg/kg/day (rounded) within 72 ± 48 hours after completion of chemotherapy until neutrophil recovery 1 x 109/L or higher. Pegfilgrastim (given at 6 mg subcutaneous for one dose approximately 24 hours after completion of the chemotherapy) may be substituted for G-CSF.
Study: NCT03248752

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit use and reports
Description: Participants will receive a Fitbit device to be used for the duration of the study. Participants will engage with the Fitbit and application and receive Weekly Progress Reports from Fitbit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitbit use and reports
Description: Participants will receive a Fitbit device to be used for the duration of the study. Participants will engage with the Fitbit and application and receive Weekly Progress Reports from Fitbit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partner engagement
Description: Participants will be connected with their partner in the Fitbit app and therefore have the ability to access their partner's progress. Participants' Weekly Progress Reports will be automatically forwarded to their partner. Participants will engage in a weekly discussion on the topic of their Weekly Progress Reports.
Study: NCT01506843

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mite, Mite and Bacterial or Placebo
Description: All treatments were given by sublingual route according to schedule of EAACI, with some modification. Patients received up-dosing sublingual drops once a day, reaching in approximately 3 months a monthly maintenance dose of 36 μg of Der p 1 given three times a week in alternate days for mite, mite and bacterial allergen extract, and no Der p 1 and no bacterial components in the placebo group. Doses were delivered by using vials equipped with a metered-dose dropper, and subjects were instructed to hold the solution under the tongue for 2 min and not to eat or drink for 60 min after the dose. Subjects self-administered the treatment at home. Adjustments in the schedule were made on an individual basis according to standard guidelines for specific immunotherapy
Study: NCT04472767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transarterial Chemoembolization
Description: TACE treatment will be administered using either the DEB-TACE or cTACE modality in a series of up to 3 individual procedures within the 9-12 weeks following Day 21 (= cycle 1 day 21) of a patient's first infusion of nivolumab/ipilimumab. The first TACE treatment should start no more than 7 working days after being cycle 1 day 21.
Study: NCT03812159

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iCSPlan
Description: The Investigator will acquire a routine pre-operative CT-scan to help assess the synostosis severity. A week before the surgery a routine preoperative visit will be done. If the potential subject agrees to participate in the study, a presurgical plan will be built, and based on the CT scan, it will (1) quantify shape differences between pathological and healthy cranial shapes; (2) compensates for brain and cranial growth during the months between diagnosis, treatment and recovery; and (3) guides bone-cuts and bone-placement for the simplest and optimal surgical procedure.~Finally this plan will be recorded in a software, iCSPlan, which will be reviewed by the surgeon. If it is accepted, it will be available during the surgery as a rely-on tool which may or may not be followed.
Study: NCT03127709

Intervention type: BEHAVIORAL
Intervention: Trail Making Test, Parts A & B
Description: Part A is a timed measure of visual scanning and graphomotor speed. Part B is a timed measure of cognitive flexibility.

Intervention type: BEHAVIORAL
Intervention: Brief Test of Attention
Description: Assesses auditory working memory

Intervention type: BEHAVIORAL
Intervention: Symbol Span
Description: Assesses visual working memory

Intervention type: BEHAVIORAL
Intervention: Controlled Oral Word Association Test
Description: The COWA timed test of phonemic verbal fluency. It requires the subject to generate as many words as possible, beginning with a given letter of the alphabet (i.e., F, A, and S).

Intervention type: BEHAVIORAL
Intervention: The Hopkins Verbal Learning Test-Revised
Description: HVLT-R is a test of verbal learning and memory. Scores obtained are the total number of words.

Intervention type: BEHAVIORAL
Intervention: Brief Visuospatial Memory Test-Revised
Description: The BVMT-R is a test of visuospatial learning and memory.

Intervention type: BEHAVIORAL
Intervention: Hospital Anxiety and Depression Scale
Description: The HADS is a brief assessment validated in many cancer populations.

Intervention type: BEHAVIORAL
Intervention: McGill Quality of Life Scale
Description: This is a questionnaire that is a validated 17-item QOL instrument validated for ill patients and in the particular context of the ancer.

Intervention type: DIAGNOSTIC_TEST
Intervention: MR Brain Imaging
Description: Standard of care brain MR imaging includes high-resolution 3D T1-weighted images in the axial plane. The axial T1-weighted images will be isotropic with a typical matrix size of 256 x 256, 256 mm field-of-view (FOV) and 1 mm slice thickness covering the whole brain.

Intervention type: DIAGNOSTIC_TEST
Intervention: Resting state functional MRI
Description: Scanning will be performed on a 3 Tesla General Electric scanner (Optima 750W) with a GEM HNU 24-channel head coil. rsFMRI matching the FLAIR and T1 post-contrast images will be obtained. For resting state fMRI, T2\*-weighted images will be acquired with a single-shot gradient echo echo-planar imaging (EPI) sequence in the axial orientation (TR = 2500 ms, TE = 30 ms, FA = 80°, slice thickness = 4 mm, FOV= 240mm2, matrix=64×64) covering whole brain. For the resting state fMRI portion of the scan, patients will be instructed by the technologist or research staff to leave eyes open, focus on looking at a crosshair, and not think about anything during the scan.

Intervention type: BEHAVIORAL
Intervention: Functional Assessment of Cancer Therapy Cognitive Scale (FACT-Cog)
Description: This is a validated 37-item QOL instrument for cancer patients with cognitive complaints. The measures consist of FACT-Cog total, perceived cognitive impairments, perceived cognitive abilities, and impact on quality of life.
Study: NCT01994161

Intervention type: PROCEDURE
Intervention: intracranial stenting
Description: all the participants in this group will be performed with intracranial stenting~--------------------------------------------------------------------------------
Study: NCT05310929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Labetalol and Glyceril trinitrate
Description: for control of blood pressure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Labetalol and Glyceril trinitrate
Description: for control of blood pressure
Study: NCT02441075

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 70% Ethanol
Description: the study will use 70% ethanol lock in the CVLs. A 2ml 70% ethanol lock will be instilled into the white lumen of the CVL for 2 hours. At the end of 2 hours, the ethanol will be withdrawn; the CVL lumen flushed with normal saline, and the CVL would be available for normal use for that day.
Study: NCT01338727

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breastfeeding Peer Counseling
Description: 3 Prenatal visits, daily in-hospital visits, 11 postpartum home visits.
Study: NCT03090620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Physostigmine
Description: Administration of physostigmine bolus followed by an infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam
Description: Administration of lorazepam bolus followed by normal saline infusion
Study: NCT02930798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987516
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code:Z46-116)
Study: NCT03747224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARO-ANG3
Description: single or multiple doses of ARO-ANG3 by subcutaneous (sc) injections

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sterile normal saline (0.9% NaCl)
Description: calculated volume to match active treatment
Study: NCT02876939

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: kinesiology tape around the hip, knee and ankle joints
Description: We will also demonstrate that taping the skin increases the central representation of cutaneous afferent input in HSAN III.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesiology tape around the hip, knee and ankle joints
Description: We will also demonstrate that taping the skin increases the central representation of cutaneous afferent input in HSAN III.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No kinesiology tape around the hip, knee and ankle joints
Description: Investigators will demonstrate that taping the skin increases the central representation of cutaneous afferent input in HSAN III.
Study: NCT05053724

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Star to move Protocol
Description: Progressive physical therapy according to the Gosslink protocol called Start to move.
Study: NCT00367016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Xolair (Omalizumab) will be given by subcutaneous injection according to Ige level and weight calculation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, given by subcutaneous injection.
Study: NCT01069796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m² weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/kg d1 d15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 800 mg/m² p.o. twice a day, D1 to D5 week 1, 2 \& 3
Study: NCT01109017

Intervention type: DRUG
Intervention: somatropin
Description: Norditropin® (somatropin) prescribed at the discretion of the physician according to normal clinical practice. Safety and effectiveness data is recorded by the physician, and a Quality of Life form is completed by the patient, at visits 1 to 5.
Study: NCT03934827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRx0518 Capsules
Description: MRx0518 is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The dosing regimen is one capsule orally twice daily for 2-4 weeks until surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRx0518/placebo Capsules
Description: MRx0518/placebo product consist of a lyophilised formulation of either a proprietary strain of bacterium or placebo.The dosing regimen is one capsule orally twice daily for 2-4 weeks until surgery. Placebo capsules are manufactured to mimic MRx0518 capsules and contain the same excipients as the active biotherapeutic product.
Study: NCT01427881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo allogeneic PBSCT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo TBI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV
Study: NCT04520412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GV-971
Description: Administered PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered PO